TP53 and colorectal cancer: Thus, it is possible that inhibitors of WNT/β-catenin signaling, though probably not LGK-974 but rather cell-intrinsic inhibitors, such as the downstream WNT/β-catenin signaling inhibitors that showed effectiveness in CSC suppression such as KYA1797K41, might be beneficial to mutant p53 harboring colorectal cancer patients, while both WNT ligand and downstream WNT/β-catenin signaling inhibitors may be useful to prevent relapse after 5-FU treatment in WT p53 harboring patients.